RHYTHM™
BIOSCIENCES



Rhythm Biosciences

An ASX Life Sciences Growth Opportunity

Q1 FY27 UPDATE: 4TH NOVEMBER 2026

ASX: RHY

Disclaimer



This presentation has been prepared by **Rhythm Biosciences Limited** (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this presentation.

This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. Rhythm makes no warranty or representation (express or implied) as to the accuracy, reliability or completeness of the information contained in this presentation. Specifically, several matters referred to in the presentation remain under investigation and are subject to change or even elimination, depending on further research and investigation. Further, any opinions (including any forward-looking statements) expressed in this presentation are subject to change without notice. Rhythm and its directors, officers, employees, advisers and agents shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, contained in or derived from or for any omissions from this presentation, except liability under statute that cannot be excluded.

This presentation, including the information contained in this disclaimer, does not form part of any offer, invitation or recommendation in respect of shares, or an offer, invitation or recommendation to sell, or a solicitation of any offer to buy, shares in the United States, or in any other jurisdiction in which, or to any person to whom, such an offer would be illegal.

This presentation may include forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks, uncertainties and assumptions, many of which are outside the control of Rhythm. Actual values, results or events may be materially different to those expressed or implied in this presentation depending on a range of factors. Given these uncertainties, recipients are cautioned not to place reliance on forward-looking statements. No representation or warranty (express or implied) is made by Rhythm or any of its directors, officers, employees, advisers or agents that any forecasts, projections, intentions, expectations or plans set out in this presentation will be achieved.

Detecting cancer earlier to save lives

Rhythm Biosciences is an ASX-listed company building a precision diagnostics platform focused on earlier cancer detection, risk assessment and improved patient outcomes.

COLOSTAT® — Non-invasive blood-based bowel cancer detection test

geneType™ — Assessing cancer risk before symptoms appear

Rhythm is positioned at the intersection of precision medicine, preventative healthcare and scalable diagnostics.



Cancer is often detected too late

Earlier detection significantly improves survival outcomes and lowers treatment costs.

RHYTHM BIOSCIENCES

15,500+


new colorectal cancer cases diagnosed every year in Australia

>50%

diagnosed as late-stage disease (Stages III or IV)

10%

5-year survival rate when diagnosed at Stage IV



Detecting cancer earlier saves lives

Two complementary platforms. One longitudinal precision cancer diagnostic strategy.

RHYTHM™ BIOSCIENCES

geneType™

RISK ASSESSMENT

Who is at risk?

Genomic cancer risk assessment that identifies elevated risk before symptoms emerge.

Assessing cancer risk before symptoms appear.

COLOSTAT®

Colorectal Cancer Test

DISEASE DETECTION

Who has the disease?

Blood-based bowel cancer detection that improves colonoscopy triage.

Non-invasive, blood-based bowel cancer detection.

Rhythm Biosciences sits at the intersection of precision medicine, preventative healthcare and scalable diagnostics – earlier detection, better outcomes, lower cost of care.

RHYTHM™ BIOSCIENCES

COLOSTAT®

Colorectal Cancer Test

A blood-based colorectal cancer detection platform designed to aid effective early diagnosis.

www.colostat.com



22 million patients waiting on a colonoscopy decision...

22M symptomatic patients could benefit from better-informed colonoscopy decisions. That's approximately **40% of annual colonoscopy** volumes worldwide.

An alternative to stool-based testing
Many patients avoid stool-based testing, delaying diagnosis


Prioritise patients at greatest risk
Help specialists identify which symptomatic patients should receive colonoscopy sooner.

Reduce unnecessary invasive procedures
Support alternative clinical management for patients less likely to benefit from colonoscopy.

Alleviate accessibility challenges
Regional and underserved communities face limited access to endoscopy facilities.

Estimated annual triage opportunity by region

Millions of potential tests per year: diagnostic colonoscopies



Global annual opportunity: 22M tests p.a.

ColoSTAT® is a simple blood test that tells the specialist who to scope first.

Scaling ColoSTAT® through established clinical channels

Clinically validated. Partner-enabled. Built for national scale.

AN ESTABLISHED MARKET

>800,000

colonoscopies performed annually in Australia

ColoSTAT® addresses patients who may not require immediate colonoscopy or who otherwise fall outside existing pathways.

A NATIONAL REFERRAL BASE

~41,000

primary care and specialist clinicians across Australia

Commercial reach through established referral pathways, supported by targeted clinician education and adoption.

EVIDENCE-LED ADOPTION

Clinical and economic evidence

Supports clinician confidence, routine use and the case for reimbursement.

RHYTHM BIOSCIENCES

Testing, analytics and commercial execution

+

4Cyte Pathology

National collection network and patient access

PARTNERSHIP-LED COMMERCIAL EXPANSION

Established infrastructure supports scalable national rollout of ColoSTAT®.

How we grow revenue

Four ColoSTAT® growth levers that multiply each other – all already in motion

LEVER 1

More doctors ordering

Making ColoSTAT® easy to order and well known to GPs and specialists.

ALREADY IN MOTION

- Live in MedicalDirector since 1 August 2026
- Best Practice ordering targeted for November 2026
- Digital campaign for patients and GPs

×

LEVER 2

More collection sites

More places close to home for patients to give a blood sample.

ALREADY IN MOTION

- 100+ 4Cyte sites across the eastern states (up from 78)
- Continued expansion planned for November 2026

×

LEVER 3

Medicare reimbursement

A Medicare listing would make ColoSTAT® more affordable for eligible patients.

ALREADY IN MOTION

- Independent study: ~$4.50 of hospital costs avoided per $1 spent on testing
- Initial MSAC engagement in Q2 FY27

×

LEVER 4

International markets

Running ColoSTAT® in partner labs overseas opens up new countries.

ALREADY IN MOTION

- NHS England lab can now run the test (technology transfer complete)
- Patient-sample testing in the NHS evaluation is next

More doctors ordering × more collection sites × Medicare funding × new international markets

= more ColoSTAT® tests, more patients helped and more revenue

Source: Rhythm Biosciences Q1 FY27 Quarterly Activities Report and Appendix 4C (27 October 2026).

ColoSTAT® demand is building

Q1 FY27: more tests, more repeat doctors, easier access

TEST VOLUMES

+56%

growth in ColoSTAT® tests on Q4 FY26

Q1 FY27 test volumes compared with the previous quarter.

REPEAT ORDERING

~20%

of requesting doctors are repeat requesters

Doctors are coming back to order ColoSTAT® again.

PATIENT ACCESS

100+

4Cyte collection sites across the eastern states

Up from 78 at the end of March 2026.

EASIER ORDERING

Live

in MedicalDirector since 1 August 2026

GPs order from their practice software – no paper forms.

REGULATORY

TGA step completed

Accepted into the TGA In-House IVD Notification Database for our NATA-accredited lab.

HEALTH ECONOMICS

~$4.50 avoided for every $1

Independent study of public hospital costs avoided per $1 spent on testing – a key input to our Medicare (MSAC) application.

INTERNATIONAL

NHS England lab can run ColoSTAT®

Technology transfer to the Royal Surrey NHS lab is complete. Patient-sample testing is next.

COMING NEXT
Q2 FY27

- Best Practice ordering for most Australian GPs (Nov 2026)
- Continued increase in 4Cyte collection centres (Nov 2026)
- Digital campaign for patients and GPs
- Initial engagement with MSAC on reimbursement
- NHS patient-sample testing begins

Source: Rhythm Biosciences Q1 FY27 Quarterly Activities Report and Appendix 4C (27 October 2026).

RHYTHM™ BIOSCIENCES

geneType™

Personalised cancer risk assessment designed to support earlier detection and prevention.

www.genetype.com




Personalised cancer risk assessment at scale

geneType™ CANCER RISK ASSESSMENT PLATFORM

RHYTHM™ BIOSCIENCES

How geneType™ reaches the market



Projected test volume mix across the forecast period, with most volume expected to come through enterprise accounts and strategic partners.

Clinics – 25%

Direct volume. healthcare professionals (B2B). Clinics provide an immediate route to patients and support early test uptake.

Enterprise – 75%

Pathology networks, health, insurance and other enterprise partners can extend access across larger populations.

A broader cancer portfolio

Six# cancer risk assessments, including three that complement Rhythm's protein biomarker programs.

- Breast*
- Prostate
- Colorectal*
- Ovarian
- Pancreatic*
- Melanoma


* Rhythm Biosciences protein biomarker program overlap.
# Lung cancer test pending transfer to production

A single platform covering six cancers, delivered through clinics and enterprise partners.

Our current commercial portfolio is supported by a comprehensive product pipeline

RHYTHM™ BIOSCIENCES

Seven tests on the market today; a pipeline across nine cancers.



	BREAST	PROSTATE	COLORECTAL	OVARIAN	MELANOMA	PANCREATIC	LUNG	GASTRIC	CERVICAL
Risk Assessment	●	●	●	●	●	●	◕	○	·
Screening	○	·	◕	·	·	○	◕	○	○
Triage	·	·	●	·	·	·	◕	○	·
Biopsy	·	·	·	·	·	·	·	·	·
Surgical Margins	·	·	·	·	·	·	·	·	·
Drug Management	·	·	·	·	·	·	·	·	·
Monitoring	·	·	·	·	·	·	·	·	·

● Commercial product
◕ Active development program
○ Near-future opportunity
· Future opportunity

FY27 Catalysts

What we delivered in Q1 and what's coming next.

Done ✓

Q1 FY27 (July – September 2026)

- ✓ ColoSTAT® ordering live in MedicalDirector (Aug 2026)
- ✓ 4Cyte collection sites passed 100 (up from 78)
- ✓ TGA In-House IVD notification completed
- ✓ ColoSTAT® health economic study completed
- ✓ NHS England technology transfer done – ahead of plan
- ✓ geneType™ US reimbursement review done – ahead of plan
- ✓ New geneType™ lung cancer risk test announced

Coming next

Q2 FY27 (OCTOBER – DECEMBER 2026)

- ColoSTAT® ordering in Best Practice (Nov 2026)
- Continued expansion of 4Cyte collection centres (Nov 2026)
- Digital campaign for patients and GPs
- Initial MSAC engagement on Medicare reimbursement
- NHS patient-sample testing begins
- FY26 R&D Tax Incentive claim lodged

IN PROGRESS

- ColoSTAT® Access Program: 19 of 20 physicians enrolled
- geneType™ strategic partnerships: partner funnel expanding

Q3 FY27 (JANUARY – MARCH 2027)

- ColoSTAT® MSAC submission (subject to pre-submission meeting)
- Interim real-world evidence analysis from the Access Program

Why Rhythm Biosciences? Why now?



Dual-platform precision diagnostics strategy

Longitudinal disease management: combining personalised risk assessment and earlier cancer detection.

Large global addressable markets

Exposure to significant and growing global cancer diagnostics demand.

Commercialisation underway

Development risks reduced. Commercial validation, partnerships and rollout progressing across several markets.

Team

Experienced diagnostics leadership executing the next phase of commercial growth



David Atkins, PhD
CEO & MD

Former CEO of Congenica (UK) & Synevo Diagnostics, Sr. Executive at Johnson & Johnson and Danaher.

Founder of Veridex – cancer molecular and cellular diagnostics (USA).

Experience in product development and commercial leadership in the global medical device and diagnostic industry. Also an active member of BioNSW and InGeNA.



Sue MacLeman
Interim Non-Executive Chair

30 years in Pharma, Biotech and Medtech including Amgen, BMS and Merck and SMEs.

Experienced Board member, former CEO of NASDAQ, ASX, & AIM entities. Currently Chair of Medicines Australia, NED & Chair at Viral Vector Manufacturing Facility, Smartways Logistics, Healthcare Translation Group, OMICO & member of the National Research Infrastructure (NRI) Advisory Group.



Carl Stubbings
Non-Executive Director

Experienced diagnostics executive, including 13 years in the USA as SVP of Panbio USA and VP Sales & Marketing at Focus Diagnostics (Quest Diagnostics).

Former CEO & MD of Sienna Cancer Diagnostics, COO of BARD1 and CCO of Genetic Technologies.

Currently Chair of Diag-Nose Medical and InGeNA, and NED of Sangui Bio.



Maureen Baker
Non-Executive Director

25+ years in investment banking and securities, including Head of Regional Equity Sales at Deutsche Bank (Hong Kong) and MD, Australian Sales at CLSA.

NED of Acorn Capital Investment Fund (ASX: ACQ), where she chairs the Risk and Audit Committee, and of Vmoto (ASX: VMT).

BCom (Melbourne), MBA (Melbourne Business School), GAICD.



Gary Goh
Head of Laboratory Operations and RA/QA



Erika Spaeth
Director of geneType™ Clinical & Scientific Affairs



Andy Feber
Director of Diagnostic Clinical & Scientific Affairs

RHYTHM™
BIOSCIENCES

RHYTHM™ BIOSCIENCES

Commercial-stage cancer diagnostics platforms entering a significant growth phase.

RHYTHM™
BIOSCIENCES

Thank you!

David Atkins, PhD

david.atkins@rhythmbio.com

www.rhythmbio.com